Logo image of TNXP

TONIX PHARMACEUTICALS HOLDIN (TNXP) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TNXP - US8902608392 - Common Stock

17.14 USD
+1.24 (+7.8%)
Last: 1/16/2026, 8:00:01 PM
16.98 USD
-0.16 (-0.93%)
After Hours: 1/16/2026, 8:00:01 PM
Fundamental Rating

3

TNXP gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for TNXP as it has an excellent financial health rating, but there are worries on the profitability. TNXP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • TNXP had negative earnings in the past year.
  • In the past year TNXP has reported a negative cash flow from operations.
  • In the past 5 years TNXP always reported negative net income.
  • In the past 5 years TNXP always reported negative operating cash flow.
TNXP Yearly Net Income VS EBIT VS OCF VS FCFTNXP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

  • TNXP has a Return On Assets of -39.30%. This is comparable to the rest of the industry: TNXP outperforms 59.81% of its industry peers.
  • TNXP's Return On Equity of -42.93% is fine compared to the rest of the industry. TNXP outperforms 69.71% of its industry peers.
Industry RankSector Rank
ROA -39.3%
ROE -42.93%
ROIC N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
TNXP Yearly ROA, ROE, ROICTNXP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • TNXP has a better Gross Margin (34.31%) than 73.52% of its industry peers.
  • TNXP does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 34.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TNXP Yearly Profit, Operating, Gross MarginsTNXP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K

More info and screens

7

2. Health

2.1 Basic Checks

  • TNXP does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for TNXP has been increased compared to 1 year ago.
  • TNXP has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for TNXP has been reduced compared to a year ago.
TNXP Yearly Shares OutstandingTNXP Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M
TNXP Yearly Total Debt VS Total AssetsTNXP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of 0.83, we must say that TNXP is in the distress zone and has some risk of bankruptcy.
  • TNXP has a Altman-Z score of 0.83. This is in the better half of the industry: TNXP outperforms 63.43% of its industry peers.
  • There is no outstanding debt for TNXP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 0.83
ROIC/WACCN/A
WACC9%
TNXP Yearly LT Debt VS Equity VS FCFTNXP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • A Current Ratio of 9.89 indicates that TNXP has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 9.89, TNXP belongs to the best of the industry, outperforming 80.57% of the companies in the same industry.
  • TNXP has a Quick Ratio of 9.62. This indicates that TNXP is financially healthy and has no problem in meeting its short term obligations.
  • TNXP has a Quick ratio of 9.62. This is amongst the best in the industry. TNXP outperforms 80.19% of its industry peers.
Industry RankSector Rank
Current Ratio 9.89
Quick Ratio 9.62
TNXP Yearly Current Assets VS Current LiabilitesTNXP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 99.62% over the past year.
  • Looking at the last year, TNXP shows a decrease in Revenue. The Revenue has decreased by -8.79% in the last year.
EPS 1Y (TTM)99.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.39%
Revenue 1Y (TTM)-8.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.58%

3.2 Future

  • The Earnings Per Share is expected to grow by 18.91% on average over the next years. This is quite good.
  • TNXP is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 72.02% yearly.
EPS Next Y99.46%
EPS Next 2Y41.32%
EPS Next 3Y25.98%
EPS Next 5Y18.91%
Revenue Next Year-16.25%
Revenue Next 2Y161.75%
Revenue Next 3Y92.27%
Revenue Next 5Y72.02%

3.3 Evolution

TNXP Yearly Revenue VS EstimatesTNXP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 20M 40M 60M 80M 100M
TNXP Yearly EPS VS EstimatesTNXP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 -500M -1B -1.5B

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

  • TNXP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year TNXP is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TNXP Price Earnings VS Forward Price EarningsTNXP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TNXP Per share dataTNXP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 -20

4.3 Compensation for Growth

  • TNXP's earnings are expected to grow with 25.98% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.32%
EPS Next 3Y25.98%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for TNXP!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

TONIX PHARMACEUTICALS HOLDIN

NASDAQ:TNXP (1/16/2026, 8:00:01 PM)

After market: 16.98 -0.16 (-0.93%)

17.14

+1.24 (+7.8%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-16
Inst Owners20.51%
Inst Owner Change-0.2%
Ins Owners0.06%
Ins Owner Change0.48%
Market Cap201.91M
Revenue(TTM)10.30M
Net Income(TTM)-99.22M
Analysts82.5
Price Target67.66 (294.75%)
Short Float %18.84%
Short Ratio3.33
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.94%
Min EPS beat(2)-17.71%
Max EPS beat(2)1.82%
EPS beat(4)3
Avg EPS beat(4)23.86%
Min EPS beat(4)-17.71%
Max EPS beat(4)97.53%
EPS beat(8)6
Avg EPS beat(8)-23.28%
EPS beat(12)8
Avg EPS beat(12)-14.25%
EPS beat(16)10
Avg EPS beat(16)-8.72%
Revenue beat(2)1
Avg Revenue beat(2)-7.73%
Min Revenue beat(2)-19.5%
Max Revenue beat(2)4.05%
Revenue beat(4)1
Avg Revenue beat(4)-12.44%
Min Revenue beat(4)-27.68%
Max Revenue beat(4)4.05%
Revenue beat(8)1
Avg Revenue beat(8)-17.18%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.97%
PT rev (3m)-1.97%
EPS NQ rev (1m)14.82%
EPS NQ rev (3m)24.31%
EPS NY rev (1m)-1.73%
EPS NY rev (3m)-2.59%
Revenue NQ rev (1m)-13.07%
Revenue NQ rev (3m)-20.28%
Revenue NY rev (1m)-6.78%
Revenue NY rev (3m)-6.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 19.6
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)-20.06
EYN/A
EPS(NY)-7.54
Fwd EYN/A
FCF(TTM)-6.48
FCFYN/A
OCF(TTM)-6.35
OCFYN/A
SpS0.87
BVpS19.62
TBVpS19.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -39.3%
ROE -42.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 34.31%
FCFM N/A
ROA(3y)-69.05%
ROA(5y)-59.72%
ROE(3y)-86.71%
ROE(5y)-72.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 77.5%
Cap/Sales 14.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.89
Quick Ratio 9.62
Altman-Z 0.83
F-Score5
WACC9%
ROIC/WACCN/A
Cap/Depr(3y)1346.5%
Cap/Depr(5y)20638.6%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)99.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.39%
EPS Next Y99.46%
EPS Next 2Y41.32%
EPS Next 3Y25.98%
EPS Next 5Y18.91%
Revenue 1Y (TTM)-8.79%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%16.58%
Revenue Next Year-16.25%
Revenue Next 2Y161.75%
Revenue Next 3Y92.27%
Revenue Next 5Y72.02%
EBIT growth 1Y-20.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y33.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y26.61%
OCF growth 3YN/A
OCF growth 5YN/A

TONIX PHARMACEUTICALS HOLDIN / TNXP FAQ

What is the fundamental rating for TNXP stock?

ChartMill assigns a fundamental rating of 3 / 10 to TNXP.


What is the valuation status of TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

ChartMill assigns a valuation rating of 1 / 10 to TONIX PHARMACEUTICALS HOLDIN (TNXP). This can be considered as Overvalued.


How profitable is TONIX PHARMACEUTICALS HOLDIN (TNXP) stock?

TONIX PHARMACEUTICALS HOLDIN (TNXP) has a profitability rating of 1 / 10.